Evidence map›Paper›PMID 39204073›Full record

ReviewVaccines2024

Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective.

Dequan Liu, Lei Liu, Xinghan Li, Shijin Wang, Guangzhen Wu, Xiangyu Che

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dequan LiuDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.ORCID 0009-0003-1242-8792
Lei LiuDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
Xinghan LiDepartment of Stomatology, General Hospital of Northern Theater Command, Shenyang 110016, China.
Shijin WangDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.ORCID 0009-0006-1140-9858
Guangzhen WuDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
Xiangyu CheDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.ORCID 0000-0003-4646-1390

Funding

the Horizontal Project Department Fund of the First Affiliated Hospital of Dalian Medical University No.2022CR015the Liaoning Provincial Education Department No.JYTMS20230577
6 · The paper itself

Abstract

With the continuous advancements in tumor immunotherapy, researchers are actively exploring new treatment methods. Peptide therapeutic cancer vaccines have garnered significant attention for their potential in improving patient outcomes. Despite its potential, only a single peptide-based cancer vaccine has been approved by the U.S. Food and Drug Administration (FDA). A comprehensive understanding of the underlying mechanisms and current development status is crucial for advancing these vaccines. This review provides an in-depth analysis of the production principles and therapeutic mechanisms of peptide-based cancer vaccines, highlights the commonly used peptide-based cancer vaccines, and examines the synergistic effects of combining these vaccines with immunotherapy, targeted therapy, radiotherapy, and chemotherapy. While some studies have yielded suboptimal results, the potential of combination therapies remains substantial. Additionally, we addressed the management and adverse events associated with peptide-based cancer vaccines, noting their relatively higher safety profile compared to traditional radiotherapy and chemotherapy. Lastly, we also discussed the roles of adjuvants and targeted delivery systems in enhancing vaccine efficacy. In conclusion, this review comprehensively outlines the current landscape of peptide-based cancer vaccination and underscores its potential as a pivotal immunotherapy approach.

Indexed as

adjuvantscombination therapydelivery systemsmechanism of actionmedication administrationpeptide-based cancer vaccines

Identifiers

PMID39204073
PMCPMC11359700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.